FI934849A - Sammansaettningar foer foerhindrande och/eller behandlande av patologiskaprocesser - Google Patents

Sammansaettningar foer foerhindrande och/eller behandlande av patologiskaprocesser Download PDF

Info

Publication number
FI934849A
FI934849A FI934849A FI934849A FI934849A FI 934849 A FI934849 A FI 934849A FI 934849 A FI934849 A FI 934849A FI 934849 A FI934849 A FI 934849A FI 934849 A FI934849 A FI 934849A
Authority
FI
Finland
Prior art keywords
lmwh
present
patologiskaprocesser
behandlande
sammansaettningar
Prior art date
Application number
FI934849A
Other languages
English (en)
Finnish (fi)
Other versions
FI934849A0 (fi
Inventor
Irun R Cohen
Ofer Lider
Rami Hershkoviz
Original Assignee
Yeda Res & Dev
Irun R Cohen
Ofer Lider
Rami Hershkoviz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL9802891A external-priority patent/IL98028A/en
Priority claimed from IL98298A external-priority patent/IL98298A0/xx
Application filed by Yeda Res & Dev, Irun R Cohen, Ofer Lider, Rami Hershkoviz filed Critical Yeda Res & Dev
Publication of FI934849A0 publication Critical patent/FI934849A0/fi
Publication of FI934849A publication Critical patent/FI934849A/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
FI934849A 1991-05-02 1993-11-02 Sammansaettningar foer foerhindrande och/eller behandlande av patologiskaprocesser FI934849A (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL9802891A IL98028A (en) 1991-05-02 1991-05-02 Pharmaceuticals containing low molecular weight heparin (HWML)
IL98298A IL98298A0 (en) 1991-05-28 1991-05-28 Pharmaceutical compositions comprising a heparin derivative
PCT/US1992/003626 WO1992019249A1 (fr) 1991-05-02 1992-05-01 Compositions pour la prevention et/ou le traitement de processus pathologiques

Publications (2)

Publication Number Publication Date
FI934849A0 FI934849A0 (fi) 1993-11-02
FI934849A true FI934849A (fi) 1993-12-31

Family

ID=26322260

Family Applications (1)

Application Number Title Priority Date Filing Date
FI934849A FI934849A (fi) 1991-05-02 1993-11-02 Sammansaettningar foer foerhindrande och/eller behandlande av patologiskaprocesser

Country Status (15)

Country Link
US (3) US5474987A (fr)
EP (1) EP0583360B1 (fr)
JP (1) JPH06507635A (fr)
KR (1) KR100235782B1 (fr)
AT (1) ATE217796T1 (fr)
AU (1) AU668865B2 (fr)
BR (1) BR9205961A (fr)
CA (1) CA2102207A1 (fr)
CZ (1) CZ232593A3 (fr)
DE (1) DE69232615T2 (fr)
FI (1) FI934849A (fr)
HU (1) HUT67136A (fr)
NO (1) NO933942L (fr)
SK (1) SK120193A3 (fr)
WO (1) WO1992019249A1 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605938A (en) 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
US6750207B1 (en) * 1992-05-01 2004-06-15 Yeda Research And Development Co. Ltd. Compositions for the regulation of cytokine activity
EP1095657B1 (fr) * 1992-11-10 2007-01-10 Yeda Research And Development Co. Ltd. Compositions pour la régulation de l'activité des cytokines
WO1994018988A2 (fr) * 1993-02-22 1994-09-01 Von Arnim Ulrich Christoph Compositions pharmaceutiques de traitement de maladies inflammatoires ou immunologiques et procede de traitement desdites maladies
US5980865A (en) * 1995-08-18 1999-11-09 Baker Norton Pharmaceuticals, Inc. Method for treating late phase allergic reactions and inflammatory diseases
CA2235223A1 (fr) 1995-10-30 1997-05-09 Massachusetts Institute Of Technology Lyases de polysaccharides designees rationnellement derivees de l'heparinase i
KR100512671B1 (ko) * 1996-11-27 2005-09-07 아벤티스 파마슈티칼스 인크. 항 Ｘａ 활성을 지닌 화합물 및 혈소판 응집 길항제 화합물을포함하는 약제학적 조성물
KR100571010B1 (ko) 1997-07-14 2006-04-13 무라마쯔 다카시 미드카인 또는 그 저해제를 유효성분으로 하는 약제
US7056504B1 (en) 1998-08-27 2006-06-06 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase I and II
JP2003527822A (ja) 1998-08-27 2003-09-24 マサチューセッツ インスティテュート オブ テクノロジー ヘパリナーゼｉおよびｉｉ由来の合理的に設計されたヘパリナーゼ
IL127851A0 (en) 1998-12-30 1999-10-28 Applied Research Systems Inhibition of TNF activity
CA2370539C (fr) 1999-04-23 2009-01-06 Massachusetts Institute Of Technology Systeme et procede de notation de polymeres
HUP0201712A3 (en) * 1999-06-30 2003-03-28 Weitz Jeffrey I Ancaster Clot associated coagulation factors inhibiting heparin compositions
CA2402160C (fr) 2000-03-08 2012-02-14 Massachusetts Institute Of Technology Heparinase iii et ses utilisations
JP2004507562A (ja) * 2000-09-08 2004-03-11 ハミルトン　シビック　ホスピタルズ　リサーチ　ディベロップメント　インコーポレイテッド 抗血栓性組成物
JP4911865B2 (ja) 2000-09-12 2012-04-04 マサチューセッツ インスティテュート オブ テクノロジー 低分子量ヘパリンに関連する方法および生成物
JP2004523479A (ja) 2000-10-18 2004-08-05 マサチューセッツ　インスティテュート　オブ　テクノロジー 多糖の肺送達に関する方法および産物
ES2238383T3 (es) * 2000-12-16 2005-09-01 Aventis Pharma Deutschland Gmbh Uso de heparina de bajo peso molecular para el tratamiento de la osteoartrosis.
WO2003000190A2 (fr) * 2001-06-25 2003-01-03 Depuy Encapsulation liposomale de glycosaminoglycanes pour le traitement d'articulations arthrosees
CA2455038A1 (fr) * 2001-07-31 2003-02-13 Board Of Regents, University Of Texas System Antigenes et anticorps pour des molecules transloquees de micro-organismes et leurs utilisations
WO2003011119A2 (fr) * 2001-07-31 2003-02-13 Reddy Us Therapeutics, Inc. Procedes et compositions pour le diagnostic et le traitement d'etats vasculaires
US7285536B2 (en) * 2001-12-05 2007-10-23 Yeda Research And Development Co., Ltd. Anti-cancer therapeutic compounds
AU2003230985A1 (en) * 2002-04-18 2003-11-03 Stephen H. Embury Method and composition for preventing pain in sickle cell patients
US8071569B2 (en) * 2002-09-20 2011-12-06 Mousa Shaker A Oxidized heparin fractions and their use in inhibiting angiogenesis
EP1592373B1 (fr) * 2003-01-30 2013-04-24 ProChon Biotech Ltd. Matrices de fibrine lyophilisees et leurs procedes de preparation
WO2005054493A2 (fr) * 2003-06-12 2005-06-16 Mayo Foundation For Medical Education And Research Activite modifiee de recepteurs de type toll
PL1641914T3 (pl) 2003-06-27 2017-01-31 DePuy Synthes Products, Inc. Komórki pochodzące z poporodowej tkanki łożyska oraz sposoby uzyskiwania i zastosowania tych komórek
US9572840B2 (en) 2003-06-27 2017-02-21 DePuy Synthes Products, Inc. Regeneration and repair of neural tissue using postpartum-derived cells
WO2005032483A2 (fr) * 2003-10-01 2005-04-14 Momenta Pharmaceuticals, Inc. Polysaccharides pour l'administration pulmonaire d'agents actifs
EP1731131A1 (fr) * 2004-03-29 2006-12-13 Kringle Pharma Inc. Accelerateur de production hgf contenant un oligosaccharide de type heparine
WO2006023487A2 (fr) * 2004-08-16 2006-03-02 Massachusetts Institute Of Technology Synthese d'anticoagulants rapide en deux etapes
ES2621847T3 (es) 2004-12-23 2017-07-05 DePuy Synthes Products, Inc. Células posparto derivadas de tejido de cordón umbilical, y métodos de elaboración y uso de las mismas
AU2006272780A1 (en) * 2005-07-22 2007-02-01 The Regents Of The University Of California Heparin compostions and selectin inhibition
CA2623106C (fr) 2005-09-19 2013-12-24 Histogenics Corporation Matrice support de cellules dont la densite des pores et la porosite sont definies specifiquement de maniere uniforme verticalement et organisees de maniere non aleatoire, et procede de preparation de celle-ci
WO2009141821A1 (fr) * 2008-05-20 2009-11-26 Crystal Clear Partnership Séparation de polysaccharides par un gradient de densité de charge
US10077420B2 (en) 2014-12-02 2018-09-18 Histogenics Corporation Cell and tissue culture container

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL61201A (en) * 1979-10-05 1984-09-30 Choay Sa Oligosaccharides having no more than 8 saccharide moieties,their obtention from heparin and pharmaceutical compositions containing them
US4281108A (en) * 1980-01-28 1981-07-28 Hepar Industries, Inc. Process for obtaining low molecular weight heparins endowed with elevated pharmacological properties, and product so obtained
CA1226816A (fr) * 1982-12-20 1987-09-15 Moses J. Folkman Inhibition de l'angrogenese
US4916219A (en) * 1985-03-28 1990-04-10 University Of Iowa Research Foundation Oligosaccharide heparin fragments as inhibitors of complement cascade
IT1214609B (it) * 1985-05-17 1990-01-18 Opocrin Spa Esosaminoglicani solfati depolimerizzati ad attivita'antitrombotica, fibrinolitica, antinfiammatoria, loro procedimento di preparazione e composizioni farmaceutiche che li contengono.
US4889808A (en) * 1985-10-01 1989-12-26 American Home Products Method of enchancing t-PA and SCU-PA production
EP0240098A3 (fr) * 1986-04-04 1989-05-10 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Oligo et Polysaccharides pour le traitement des maladies causées par des rétrovirus
US4788307A (en) * 1986-04-30 1988-11-29 Choay S.A. Oligosaccharidic fractions devoid or practically devoid of antithrombotic activity
ES2059321T3 (es) * 1986-05-16 1994-11-16 Italfarmaco Spa Heparinas, fracciones y fragmentos de heparinas libres de edta, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
WO1988000017A1 (fr) * 1986-06-27 1988-01-14 Boon Corporation Pty. Ltd. Dessous de plat ou de verre
IL85145A (en) * 1987-01-23 1994-08-26 Univ Australian Anti-metastatic pharmacological or veterinary preparations containing modified herpin with reduced anticoagulant activity
FR2614026B1 (fr) * 1987-04-16 1992-04-17 Sanofi Sa Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques
SE8702254D0 (sv) * 1987-05-29 1987-05-29 Kabivitrum Ab Novel heparin derivatives
AU4426289A (en) * 1988-10-05 1990-05-01 Nicola Diferrante Methods for interfering with hiv multiplication and composition for the treatment of aids
IL88554A0 (en) * 1988-12-01 1989-07-31 Hadassah Med Org Compositions containing a compound binding to a heparin receptor
PT93847A (pt) * 1989-04-24 1990-11-20 Harvard College Processo para a preparacao de oligossacaridos de baixo peso molecular derivados de heparina ou de sulfato de heparano despolimerizados e de composicoes farmaceuticas que os contem
AT500533B8 (de) * 2000-04-13 2007-02-15 Man Nutzfahrzeuge Ag Gas- oder trolleybus

Also Published As

Publication number Publication date
HUT67136A (en) 1995-02-28
KR100235782B1 (ko) 1999-12-15
CA2102207A1 (fr) 1992-11-03
SK120193A3 (en) 1994-07-06
HU9303110D0 (en) 1994-01-28
BR9205961A (pt) 1994-07-26
JPH06507635A (ja) 1994-09-01
US5908837A (en) 1999-06-01
AU668865B2 (en) 1996-05-23
DE69232615T2 (de) 2003-01-30
ATE217796T1 (de) 2002-06-15
NO933942L (no) 1993-12-14
US5686431A (en) 1997-11-11
EP0583360A4 (fr) 1994-04-06
FI934849A0 (fi) 1993-11-02
DE69232615D1 (de) 2002-06-27
NO933942D0 (no) 1993-11-01
EP0583360B1 (fr) 2002-05-22
CZ232593A3 (en) 1994-07-13
WO1992019249A1 (fr) 1992-11-12
US5474987A (en) 1995-12-12
EP0583360A1 (fr) 1994-02-23
AU1913192A (en) 1992-12-21

Similar Documents

Publication Publication Date Title
FI934849A (fi) Sammansaettningar foer foerhindrande och/eller behandlande av patologiskaprocesser
ATE232102T1 (de) Behandlung von arthrose, rheumatoider arthrose und erscheinungen verwandt an arthrose
MY101207A (en) Treatment of diseases caused by retroviruses
ATE150469T1 (de) Mitogenfreie substanz, deren herstellung sowie verwendung
AR012614A1 (es) Una composicion farmaceutica para la fabricacion de un medicamento destinado para el tratamiento de una infeccion viral susceptible de tratamientocon interferon alfa, un metodo para la fabricacion de un medicamento, el uso de peg12000-ifn alfa para la fabricacion de un medicamento
PT921787E (pt) Regime de administracao de inibidores de atpase de h',k'
SE9600716L (sv) Adhesionsinhibitorer, preparat innehållande desamma och förfarande för framställning därav
ES2173858T3 (es) Analogos de huperzina a.
Rouse et al. Host defense mechanisms against infectious bovine rhinotracheitis virus: II. Inhibition of viral plaque formation by immune peripheral blood lymphocytes
ES551436A0 (es) Proceso para la fabricacion de compuestos de espiro-hidantoina
EE04044B1 (et) Farmatseutilised tooted veresoonte endoteelirakkude kahjustuste tagajärjel tekkinud haiguste raviksja vältimiseks
FR2378855A1 (fr) Nouvelles glycoproteines isolees d'hafnia, procede de preparation et application a titre de medicaments
DE69433110D1 (de) Allogenes vakzin und synthesemethode für selbiges
Kaufmann et al. Attempts to characterize the T-cell population and lymphokine involved in the activation of macrophage oxygen metabolism in murine listeriosis
RU93058322A (ru) Композиции для предотвращения и/или лечения патологических процессов, способ применения низкомолекулярного гепарина, способ лечения
YOSHIOKA et al. The role of anti-asialo GM1 antibody-sensitive cells in the implementation of tumor-specific T cell-mediated immunity in vivo
ES476703A1 (es) Procedimiento para preparar una heterovacuna para el trata -miento terapeutico del sindrome de los triconomas.
NO974651L (no) Biologisk aktive ureidoderivater som er nyttige i behandlingen av multippel sklerose
Cohen et al. Methods of using low molecular weight heparins treatment of pathological processes
Morales et al. Experimental immunotherapy with NK-like cells: A preliminary report
CN116687930A (zh) 吐根碱在制备防治电离辐射致放射性肺损伤药物中的应用
IWAGUCHI et al. Effect of chemotherapeutic agents on the growth of rat bladder cancer, BC-47
UA28523A (uk) Спосіб пригнічення репродукції вірусу імунодефіциту людини
PT1165596E (pt) Derivados de 14,15-alfa-metileno equilenina processos para producao dos mesmos e medicamentos que os contem
RU97117918A (ru) Способ адаптивной иммунотерапии злокачественных новообразований

Legal Events

Date Code Title Description
FD Application lapsed